Navigation path

Themes
Agriculture & food
Energy
Environment
ERA-NET
Health & life sciences
Human resources & mobility
Industrial research
Information society
Innovation
International cooperation
Nanotechnology
Pure sciences
Research infrastructures
Research policy
Science & business
Science in society
Security
SMEs
Social sciences and humanities
Space
Special Collections
  Avian & pandemic flu
  Cancer
  Earthquakes
  Floods
  HIV & AIDS
  Malaria
  Stem cells
  Volcanoes
  Water
Transport

Countries
Countries
  Argentina
  Australia
  Austria
  Belarus
  Belgium
  Benin
  Botswana
  Brazil
  Bulgaria
  Cameroon
  Canada
  Chile
  China
  Colombia
  Croatia
  Cyprus
  Czech Republic
  Denmark
  Egypt
  Estonia
  Finland
  France
  Georgia
  Germany
  Ghana
  Greece
  Hungary
  Iceland
  India
  Ireland
  Israel
  Italy
  Japan
  Kazakhstan
  Kenya
  Korea
  Latvia
  Lichtenstein
  Lithuania
  Luxembourg
  Madagascar
  Malta
  Mexico
  Montenegro
  Morocco
  Namibia
  Netherlands
  Nigeria
  Norway
  Peru
  Poland
  Portugal
  Romania
  Russia
  Senegal
  Serbia
  Slovakia
  Slovenia
  South Africa
  Spain
  Swaziland
  Sweden
  Switzerland
  Taiwan
  Tanzania
  Tunisia
  Turkey
  Uganda
  Ukraine
  United Kingdom
  United States


   Special Collections

Last Update: 29-07-2014  
Related category(ies):
Health & life sciences  |  Special Collections

 

Countries involved in the project described in the article:
France  |  Germany  |  Ireland  |  Israel  |  United Kingdom
Add to PDF "basket"

At the threshold of personalised cancer treatment

New tumour profiling methods developed by EU-funded researchers aim to help doctors adjust treatments for colorectal cancer to the specific needs of an individual patient. The methods are currently at the trial stage and could be in use in clinics within three years.

Illustration of cancerous cells

© vitanovski - Fotolia

Worldwide, colorectal cancer is responsible for around 694 000 deaths each year, according to the World Health Organization. Decision making on treatment in the clinic currently depends largely on factors such as how much the tumour has grown and the age of a patient. As each patient is unique, the success of such treatments is largely unpredictable.

To replace the 'one size fits all' approach, the APO-DECIDE project, led by Professor Jochen Prehn at the Royal College of Surgeons in Ireland, is developing new clinical decision-making tools to help doctors categorise patients on the basis of their individual biological and genetic characteristics.

"There are numerous genes and pathways altered in human cancers, and no single patient is like another,” says Prof. Prehn. “We now need to employ computational approaches to understand the complexity of genes and protein altered in individual cancer patients.”

Such computational approaches (also termed systems biology approaches) use mathematics to explore how proteins interact with each other, and how these interactions produce a biological, clinically relevant effect.

The crux of cancer treatment lies with apoptosis, or programmed cell death. Current chemotherapy treatments increase apoptosis in the tumour or nudge the cells along the path to self-destruction. Using the APO-DECIDE system, an oncologist will be able work out the dose of apoptosis promoter required on an individual basis, meaning the patient receives a dose best suited to treat their tumour right from the start.

"The tools developed in APO-DECIDE will deliver the right chemotherapy to the right patient at the right time, hence avoiding unnecessary side-effects and accelerating access to better treatments," says Prof. Prehn.

Understanding the patient – and the tumour

Tumours can become unresponsive to chemotherapy. They are made of different types of cells and many develop resistance to chemotherapy drugs. For example, for one particular type of colorectal cancer, up to 50-60 % of patients prove unresponsive to a commonly used treatment regime.

To get the treatment right, APO-DECIDE, which ends in November 2014, is not only considering differences between patients – it is also analysing the cancer at a molecular level. This information will then be used to identify weak spots in the tumour that can then be targeted with new drugs (‘apoptosis sensitisers’) that reprogramme tumour cells to respond to treatment.

This strategy avoids a situation in which a patient who is not responsive to the drugs has to endure harsh chemotherapy treatment needlessly. Analysing the chemical pathways (strings of biochemical reactions) in a tumour prior to therapy and knowing that the tumour will be responsive also reduces uncertainty, and means that scarce resources can be used to maximum benefit.

Extending the technology to other cancers

Prof. Prehn says researchers now widely accept that the chemical roots of a tumour resistance to treatment are shared by most cancer cell types. As common pathways are responsible for a tumour not responding to chemotherapy drugs, the results of APO-DECIDE may be helpful in the battle against many other types of cancer.

And the results will help to do more than personalise treatment. As well as using knowledge about the biochemical pathway to re-sensitise cancer cells, APO-DECIDE is also making the reverse possible. A new process can de-sensitise normal cells vulnerable to damage during chemotherapy, such as bone marrow stem cells.

Trials are underway, involving 600 patients. If they go as expected, doctors could be using the APO-DECIDE technology in clinics in two to three years' time.

APO-DECIDE’s research stands to provide real benefits for cancer patients. Prof. Prehn summarises the impact on clinical practice: "Such a systems-wide model approach can deliver a new generation of patient analysis tools that inform oncologists and health care providers about the type and dosage of chemotherapy that is best suited for individual patients."

 

Project details

  • Project acronym: APO-DECIDE
  • Participants: Ireland (Coordinator), UK, France, Germany, Israel
  • Project FP7 306021
  • Total costs: € 3 896 336
  • EU contribution: € 2 999 482
  • Duration: November 2012 - October 2014

Convert article(s) to PDF

No article selected


loading


Search articles

Notes:
To restrict search results to articles in the Information Centre, i.e. this site, use this search box rather than the one at the top of the page.

After searching, you can expand the results to include the whole Research and Innovation web site, or another section of it, or all Europa, afterwards without searching again.

Please note that new content may take a few days to be indexed by the search engine and therefore to appear in the results.

Print Version
Share this article
See also
Project web site
Project information on CORDIS






  Top   Research Information Center